Posted on Monday 3 June 2019 by John Mulgrew
Pharma giant Almac has seen its turnover soar to £548m as its headcount rises by almost 400 in the last year.
The Craigavon-based global firm has reported a £17m rise in turnover for 2017-18.
Pre-tax profits were recorded at £27m, down from £33m a year earlier.
In the last year the firm has made a series of major investments including further development of its European campus in Dundalk, along with a multi-million pound expansion of capacity at its site in Athlone in addition to further investment at its existing facilities in the UK, US and Asia.
Alan Armstrong, group chief executive, said: “Almac experienced yet another strong year in 2018 with our key financial and global employee metrics increasing. We made significant progress on our ambitious growth strategy with the acquisition of BioClin Laboratories and the continued investment in our existing global facilities, in addition to increased headcount.
“With 100% of our profits reinvested into the business, we will continue to innovate and improve our wide range of services and products to ensure we provide the premium solutions our global client base relies on.”